Humanigen — KaloBios Pharmaceuticals — Investor Presentation (October 2016)
39 slides from Humanigen's investor presentation, Oct 14, 2016
Slide 1: Advancing Medicines for Neglected and Rare Diseases Through Innovative Business Models
Advancing Medicines for Neglected and Rare Diseases Through Innovative Business Models OTC: KBIO www.kalobios.com | Corporate Overview - October 14, 2016 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements | Corporate Overview 2 This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and ex
Slide 3: Compelling Investment Opportunity
Turnaround focused on high-value neglected and rare diseases, including pediatricPipeline of products with multiple potential near- and longer-term catalystsBenznidazole: anticipated streamlined US approval process relying on existing data; potentially eligible for Priority Review Voucher (PRV) that
Slide 4: Two-Pronged Value Model: a Unique Approach To Near-Term Return Propelling Long-Term Value Creation
Two-Pronged Value Model: a Unique Approach To Near-Term Return Propelling Long-Term Value Creation | Corporate Overview 4 Smart Investment in underappreciated assets Leverage FDA incentives for better efficiency Value Options From multiple FDA catalysts like PRV Value Creation Potential robust comme
Slide 5: Leadership
Leadership Cameron Durrant, MD, MBAChairman and CEOSenior pharmaceutical and biotech exec, turnaround specialistSenior exec roles at Pharmacia/Pfizer, J+J in US, Merck, GSK in Europe; experience as Exec Chairman, CEO and CFO; CEO roles at three specialty pharma groupsExpertise in anti-infectives, pe
Slide 6: Board of Directors
Board of Directors Cameron Durrant, MD, MBAChairman | Corporate Overview 6 Ronald Barliant, JDOf Counsel at Goldberg Kohn, extensive experience representing debtors and creditors in complex bankruptcy casesUnited States bankruptcy judge for the Northern District of Illinois 1988 to 2002Dale Chappell
Slide 7: KaloBios Turnaround Momentum Builds: Rising from the Ashes
KaloBios Turnaround Momentum Builds: Rising from the Ashes | Corporate Overview 7 Funding dead-end, winding down Oct 2015 Martin Shkreli investment late Nov 2015 Shkreli arrest, indictment Dec 2015 Chapter 11 filing Dec 2015 Delisted by Nasdaq Jan 2016 Two new board members Jan 2016 New CEO Mar 2016
Slide 8: Neglected and Rare Disease Assets with Promise to Deliver
Neglected and Rare Disease Assets with Promise to Deliver | Corporate Overview 8 BENZNIDAZOLEPotential value generator near-term if approvedOral monotherapy with extensive history treating life-threatening infection with 60-day course Preferred treatment for Chagas disease, a neglected tropical dise
Slide 9: Current Pipeline
Current Pipeline | Corporate Overview 9 Pre-clin Phase I Phase II Phase III Target NDA/BLA Benznidazole (potential PRV)Chagas diseaseAnti-infective LenzilumabCMML Anti-GM-CSF mAb Lenzilumab (potential PRV)JMML (peds) – dependent on interim data in CMMLAnti-GM-CSF mAb Ifabotuzumab (potential PRV)Soli
Slide 10: Anticipated KaloBios Milestones
Anticipated KaloBios Milestones* Potential FDA Meeting Minutes IND SubmissionPotential Orphan Designation Bioavailability Results CMML P1 interim dataCMML Orphan designationJMML FDA meeting Other potential FDA designations JMML Orphan/RPD designationOther potential FDA designationsJMML P1 first pati
Slide 11: Priority Review Vouchers (PRVs) Create Options For Significant Potential Return
Priority Review Vouchers (PRVs) Create Options For Significant Potential Return existing PRV programs | Corporate Overview 11 Highest disclosed sale price so far for PRV is $350MM Rare Pediatric Diseases (RPD) Neglected Tropical Diseases (NTD) FDA can award a PRV for eligible products upon approvalM
Slide 12: Two-Year Outlook: We Expect PRV Policy to Remain Generally Stable
Two-Year Outlook We Expect PRV Policy to Remain Generally Stable Zika virus highlights importance of NTD incentives Post-election, congressional gridlock expected to continueFocus likely on big issues: Medicare Part D, Affordable Care Act May be less political will to change small issuesAdditional P
Slide 13: Benznidazole a potential treatment for Chagas disease
Benznidazole a potential treatment for Chagas disease | Corporate Overview 13
Slide 14: Chagas Disease
On FDA list of NTDs eligible for PRVNeglected tropical disease presenting in the US and other nations Currently no FDA-approved treatmentsImmediate need for reliable benznidazole supply in US and abroad CHAGAS disease | Corporate Overview 14 Insect carries the parasite called Trypanosoma cruzi Infec
Slide 15: Benznidazole: the Preferred Treatment Globally for Chagas
Benznidazole: the Preferred Treatment Globally for Chagas | Corporate Overview 15 40 years of clinical experience, primarily in Latin AmericaUsed in tens of thousands of patients Believed to work by inducing free radicals causing DNA damage within the T. cruzi parasite Efficacy ~60% or more in child
Slide 16: Benznidazole Has Potential for 505(b)(2) New Drug Application
Benznidazole Has Potential for 505(b)(2) New Drug Application | Corporate Overview 16 Less complexity in overall dossierOur manufacturing validation will be similar to that for a new drug – a competitive advantage 505(b)(2) Hybrid between an ANDA and full NDATo demonstrate efficacy & safety, some da
Slide 17: Benznidazole Strategy Is to Be First to US Approval
Benznidazole Strategy Is to Be First to US Approval | Corporate Overview 17 SPEEDUtilizing a combination of published literature and existing studies to demonstrate efficacy and safety of benznidazole SAFETYDemonstrating comparable bioavailability and/or bioequivalence with a reference benznidazole
Slide 18: Benznidazole Target Approval Plan
2016 2017 H1 H2 H1 H2 Manufacturing (CMC) Analytical methods development Drug substance Drug product Stability studies Non-Clinical (Non-Human) Metabolism / PK Toxicity assessment T.cruzi biology Environmental assessment Clinical Summary of relevant clinical studies Right of Reference & data extract
Slide 19: Benznidazole Clinical Profile Treating Chagas Is Well Known
Benznidazole Clinical Profile Treating Chagas Is Well Known | Corporate Overview 19 Source Study Design Age Follow Up Sample Size Treatment Groups Primary Endpoint Sosa Estani et al 1998 Randomized, double-blind 6-12 48 mo. 106 BNZ 5 mg/kg/d x 60 days (n=55)vs.Placebo (n=51) Negative Serology De And
Slide 20: Lenzilumab a potential pipeline in a product
Lenzilumab a potential pipeline in a product | Corporate Overview 20
Slide 21: KaloBios Humaneered Platform
KaloBios Humaneered® Platform Murine segments replaced by human sequences from human donor libraryNew segments have amino acid identity very near to human germ-line segments | Corporate Overview 21 THERAPEUTIC GOALS Proprietary and patented technology platform to engineer antibodies, typically murin
Slide 22: CMML Overview
High unmet needPatients typically unsuitable for stem cell transplant40-90% patients show hypersensitivity to GM-CSF CMML overview | Corporate Overview 22 Recently classified as separate disease with distinct natural history* Median overall survival rate in months Newly diagnosed US patients per yea
Slide 23: JMML Overview
No FDA-approved treatmentClear unmet needPotential for a rare pediatric disease PRVGM-CSF hypersensitivity is hallmarkPediatric oncology largely ignored in clinical development JMML overview | Corporate Overview 23 Event-free survival rate at 5 years (with bone marrow transplant) New US cases per ye
Slide 24: Mutations Affect GM-CSF Signaling, Confers Hypersensitivity in Leukemias
Neutralization of GM-CSF inhibits JAK-STAT and RAS signaling pathways in leukemic cells Mutations Affect GM-CSF Signaling, Confers Hypersensitivity in Leukemias | Corporate Overview 24 Inactivation of the NF1 tumor suppressor gene or oncogenic mutations in NRAS, KRAS2, CBL, or PTPN11. The values in
Slide 25: Lenzilumab Has Strong Potential as an Inhibitor of GM-CSF
Lenzilumab Has Strong Potential as an Inhibitor of GM-CSF | Corporate Overview 25 Potently decreases effect of GM-CSF, shows potential to kill leukemia cells in pre-clinical studies Encouraging safety profile in multiple studies with >90 patientsPotential FDA Breakthrough Therapy and Rare Pediatric
Slide 26: Strong Correlation Between GM-CSF Sensitivity, CMML / JMML
pSTAT5 Heat Map showing GM-CSF responsive populations Kotecha et al 2008 Strong Correlation Between GM-CSF Sensitivity, CMML / JMML | Corporate Overview 26
Slide 27: Lenzilumab is a Potent Inhibitor of GM-CSF Function In Vitro
Lenzilumab is a Potent Inhibitor of GM-CSF Function In Vitro | Corporate Overview 27 Inhibits GM-CSF-dependent Proliferation of Human TF-1 Leukemia Cells Blocks GM-CSF-induced STAT5 Phosphorylation in Human TF-1 Leukemia Cells Source: KaloBios laboratory notebook STAT5 phosphorylation detection in T
Slide 28: Lenzilumab Has an Established Safety Profile in Patients
Lenzilumab Has an Established Safety Profile in 94 Patients | Corporate Overview 28 Study* Population Objectives Enrollment/Dose Safety Results Phase 1 Single-dose, dose-escalation Healthy adult volunteers Safety/tolerabilityPKImmunogenicity (n=12)3 / 1 mg/kg3 / 3 mg/kg3 / 10 mg/kg3 / placebo Clean
Slide 29: Lenzilumab Holds Niche in GM-CSF
Lenzilumab Holds Niche in GM-CSF | Corporate Overview 29 Source: Wicks, I. P. & Roberts, A. W. (2015) Targeting GM‑CSF in inflammatory diseases. Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2015.161 GM-CSF Lenzilumab Humanized monoclonal antibody Asthma (moderate to severe) Lenzilumab (400mg) or placebo
Slide 30: Lenzilumab Phase Clinical Evaluation Builds and Transitions from CMML to JMML
Lenzilumab Phase 1 Clinical Evaluation Builds and Transitions from CMML to JMML PRIMARY OBJECTIVE: Maximum tolerated dose or recommended phase 2 dose; safety and tolerabilitySECONDARY OBJECTIVES: Preliminary efficacy, PK/PD biomarkers Expect consortium or cooperative group-led study of 10-15 sites*
Slide 31: Lenzilumab CMML/JMML Planned Clinical Trial Execution Matrix
Lenzilumab CMML/JMML Planned Clinical Trial Execution Matrix | Corporate Overview 31 2016 2017 2018 2019 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 CMML Phase 1 Dose Escalation Study Phase 1b/2 Expand Single Arm + Combination Study First patient dosed Preliminary safety/activity data Interim analysis ASH ab
Slide 32: Lenzilumab: a Pipeline in a Drug Opportunity
Lenzilumab: a Pipeline in a Drug Opportunity | Corporate Overview 32 JMML ALPS / RALD Cytokine Release Syndrome AMML RASopathies (e.g. CFC syndrome, Costello syndrome) Noonan Syndrome with PTPN11 CMML CML Plexiform Neurofibroma Pediatric Multiple Sclerosis US ADDRESSABLE POPULATION 325 350 500 600 7
Slide 33: Ifabotuzumab significant potential for partnering and development
Ifabotuzumab significant potential for partnering and development | Corporate Overview 33
Slide 34: Ifabotuzumab: Several Mechanisms to Lead to Tumor Cell Killing
Ifabotuzumab: Several Mechanisms to Lead to Tumor Cell Killing, Disruption | Corporate Overview 34 Brain cancer is now #1 killer pediatric cancer, according to CDCPotential in solid tumors, including rare pediatric tumors; PRV potentialEvaluating phase 0/I bio-distribution study in rare solid tumors
Slide 35: Ifabotuzumab Target Affects Cell Positioning, Survival, Tumor Growth
Ifabotuzumab Target Affects Cell Positioning, Survival, Tumor Growth EphA3Receptor tyrosine kinaseImportant in fetal developmentNot on normal adult tissuesRe-expressed on cancer and certain non-malignant diseasesUpregulated by some chemotherapeutic agents (HMAs, HDACs) and hypoxiaTarget accessible t
Slide 36: Ifabotuzumab Has Four Postulated Mechanisms of Action
1 2 3 4 Ifabotuzumab Has Four Postulated Mechanisms of Action | Corporate Overview 36 ADCC Mediated Killing of Tumor Cells Direct Apoptosis of Tumor Cells Disruption of Tumor Vasculature through Cell Rounding Anti-fibrotic Effect Ifabotuzumab Ifabotuzumab Ifabotuzumab Ifabotuzumab
Slide 37: Capitalization Summary as of 10/4/16
Capitalization Summary as of 10/4/16 | Corporate Overview 37 Debt $1.2 million Common Shares Outstanding 14.9 million Stock Options (WAEP $5.82) 2.0 million Warrants (WAEP $14.24) 0.3 million Fully Diluted Shares Outstanding 17.3 million
Slide 38: Demonstrated History of Swift Execution in Challenging Circumstances
Demonstrated History of Swift Execution in Challenging Circumstances | Corporate Overview 38 JUN JUL AUG SEP OCT Emerge in six months from complex Chapter 11 bankruptcy Lenzilumab Phase 1 trial started Extinguished Martin Shkreli’s stake in the company Current with Securities and Exchange Commission
Slide 39: Summary
Summary Unique near-term/long-term potential value creation opportunity Thoughtful business strategy that leverages existing U.S. regulatory and development incentivesAttractive asset portfolio with multiple potential milestones and partnering prospectsDeeply committed and focused new management tea
KaloBios Pharmaceuticals — Investor Presentation (October 2016) on 6ix